GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argenica Therapeutics Ltd (ASX:AGN) » Definitions » Long-Term Debt

Argenica Therapeutics (ASX:AGN) Long-Term Debt : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Argenica Therapeutics Long-Term Debt?

Argenica Therapeutics's Long-Term Debt for the quarter that ended in Dec. 2023 was A$0.00 Mil.


Argenica Therapeutics Long-Term Debt Historical Data

The historical data trend for Argenica Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argenica Therapeutics Long-Term Debt Chart

Argenica Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Long-Term Debt
- - -

Argenica Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Long-Term Debt Get a 7-Day Free Trial - - - - -

Argenica Therapeutics  (ASX:AGN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


Argenica Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Argenica Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Argenica Therapeutics (ASX:AGN) Business Description

Traded in Other Exchanges
N/A
Address
117 Broadway, Unit 4, Nedlands, WA, AUS, 6009
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.

Argenica Therapeutics (ASX:AGN) Headlines

No Headlines